JAB-23E73 / Jacobio Pharma, AstraZeneca - LARVOL DELTA

Pipeline Highlights: pan-KRAS inhibitor JAB-23E73 (Jacobio Press Release) - "As of Jan. 15, 2026, a total of 42 patients had been enrolled in the Phase I study in China. Grade 3 treatment-related adverse events were reported in 11.9% of patients, and no Grade 4 or Grade 5 treatment-related adverse events were observed. Among 13 pancreatic cancer patients treated within the predicted efficacious dose range — including two second-line and eleven third-line or later patients [AW3.1]— the objective response rate (ORR), including both confirmed and unconfirmed responses, was 38.5%, and the disease control rate (DCR) was 84.6%."

P1 data • Solid Tumor

In February 2026, China’s Center for Drug Evaluation approved a Phase I/III clinical trial evaluating JAB-23E73 in combination with nab-paclitaxel and gemcitabine as a first-line treatment for KRAS-mutant pancreatic ductal adenocarcinoma. (Jacobio Press Release)

New trial • Pancreatic Ductal Adenocarcinoma

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration (clinicaltrials.gov) - P1/2 | N=334 | Recruiting | Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • Oncology • Solid Tumor • KRAS

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 (PRNewswire) - "AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China. Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as tiered royalties on net sales achieved outside of China. AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China."

Licensing / partnership • Solid Tumor

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration (clinicaltrials.gov) - P1/2 | N=294 | Recruiting | Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Preclinical investigation of orally bioavailable, potent pan-KRAS (ON/OFF) inhibitorJAB-23E73 (AACR-NCI-EORTC 2025) - P1/2 | "JAB-23E73 is a highly potent, orally bioavailable pan-KRAS (ON/OFF) inhibitor with strong selectivity to spare HRAS and NRAS inhibition. It exhibited superior antitumor activity and good tolerability in KRAS-driven mouse tumor models. JAB-23E73 is currently in Phase I clinical trials for patients with advanced solid tumors harboring KRAS gene alterations (NCT06959615 in China and NCT06973564 in the US)."

Preclinical • Oncology • Solid Tumor • HRAS • KRAS • NRAS

Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference (PRNewswire) - "The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification."

Preclinical • Solid Tumor

JAB-23E73 (pan-KRAS inhibitor) (PRNewswire) - "Preclinical data to be presented at the AACR-NCI-EORTC International Conference in October 2025. Phase I results readout expected in the first half of 2026."

P1 data • Preclinical • Solid Tumor

JACOBIO COMPLETED THE FIRST PATIENT DOSAGE IN THE PHASE I/IIA CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN U.S. (HKEXnews) - " The board (the 'Board') of directors (the 'Director(s)') of the Company is pleased to announce that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS inhibitor JAB-23E73 in U.S. In parallel, the dose-escalation study in China is progressing as planned."

Trial status • Solid Tumor

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration (clinicaltrials.gov) - P1/2 | N=334 | Recruiting | Sponsor: Jacobio Pharmaceuticals Co., Ltd.

New P1/2 trial • Oncology • Solid Tumor • KRAS

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration (clinicaltrials.gov) - P1/2 | N=294 | Not yet recruiting | Sponsor: Jacobio Pharmaceuticals Co., Ltd.

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Jacobio Pharma Announces 2024 Annual Results (PRNewswire) - "JAB-23E73: The dose escalation phase is expected to be completed in the second half of 2025."

Trial status • Oncology • Solid Tumor

Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor (Jacobio Press Release) - "Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has completed the first patient dosage of Pan-KRAS inhibitor (JAB-23E73) in the Phase I/IIa clinical study in China."

Trial status • Oncology

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE (Jacobio Press Release) - "Jacobio Pharma...announced that it received IND (investigative new drug) approval from the China CDE....JAB-23E73 can inhibit both the active ('ON'）and inactive ('OFF') states of KRAS and with no obvious inhibition to HRAS or NRAS."

New trial • Oncology • Solid Tumor

Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA (Jacobio Press Release) - "Jacobio Pharma...announced that it received IND (investigative new drug) approval from the U.S. FDA of Pan-KRAS inhibitor JAB-23E73, and Jacobio plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The China IND has been submitted, and China clinical trial will be initiated after China IND approval...JAB-23E73 can inhibit both the active ('ON'）and inactive ('OFF') states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data showed good pharmacokinetic profile."

IND • New P1/2 trial • Solid Tumor

Jacobio Pharma Announces 2023 Annual Results (PRNewswire) - "KRASmulti inhibitor JAB-23E73: The IND application is expected to be submitted in Q2 2024; Clinical candidate for HER2-STING iADC JAB-BX400 is expected to be nominated in the second half of 2024."

Clinical • IND • Oncology • Solid Tumor